Stockreport

Vaxcyte Advances Adult and Infant Programs for VAX-31, a Potential Best-in-Class, Next-Generation Pneumococcal Conjugate Vaccine [Yahoo! Finance]

Vaxcyte, Inc.  (PCVX) 
PDF Vaccine (OPUS-2) and Expects to Initiate Phase 3 Study in Adults Previously Vaccinated with Pneumococcal Vaccines (OPUS-3) in First Quarter of 2026 Company Expects to [Read more]